Top Industry Leaders in the Kidney Infection Market
Latest Kidney Infection Companies Updates:
GSK's gepotidacin (Gepotidacin) receives positive Phase 3 results: This November 2023 news signifies a potential breakthrough with gepotidacin demonstrating high efficacy against UTIs, especially in multidrug-resistant strains.
FDA approval of fosfomycin trometamol for uncomplicated UTIs: This July 2023 approval in the US provides an alternative option for treating uncomplicated UTIs, particularly for patients with limited treatment choices due to antibiotic resistance.
List of Kidney Infection Key companies in the market:
- AbbVie, Inc. (U.S.)
- Allergan plc. (U.K)
- Amgen Inc. (U.S.)
- AstraZeneca (U.K)
- F. Hoffmann-La Roche Ltd (Switzerland)
- GlaxoSmithKline plc. (U.K)
- Johnson & Johnson Services Inc. (U.S.)
- Keryx Biopharmaceuticals, Inc. (U.S.)
- Kissei Pharmaceutical Co. Ltd. (Japan)
- Pfizer (U.S.), Sanofi (France)
- Teva Pharmaceutical Industries Ltd. (Japan)